Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its glucose monitoring products, the G6 and G7, which could pose health risks to users [1]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable than previous versions [1]. - It is claimed that these changes presented a material health risk to users who depend on these devices for accurate glucose readings [1]. - The lawsuit asserts that the enhancements to the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [1]. - The defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [1]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [1]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [3]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing health risks to users relying on accurate glucose readings [3]. - DexCom is accused of overstating the enhancements and reliability of the G7 device while downplaying the severity of issues related to adulterated devices [3]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [3]. Group 2: Legal Process and Representation - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiffs in the class action [4]. - A lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4]. - Investors can choose to remain absent from the proceedings without affecting their ability to share in any recovery [4].

Core Insights - Brown Advisory Mid-Cap Growth Strategy underperformed its benchmark, the Russell Midcap® Growth Index, which increased approximately 3% in Q3 2025 [1] Company Overview - DexCom, Inc. (NASDAQ:DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems [2] - As of December 17, 2025, DexCom's stock closed at $65.75 per share, with a market capitalization of $26.086 billion [2] Financial Performance - For Q3 2025, DexCom reported global revenue of $1.21 billion, an increase from $994 million in Q3 2024 [4] - The one-month return of DexCom was 13.90%, but its shares lost 12.24% of their value over the last 52 weeks [2] Market Sentiment and Challenges - DexCom exceeded second quarter consensus expectations, but a modest guidance increase did not reflect year-to-date strength, impacting market sentiment [3] - A short report raised concerns about yield, accuracy, and injury rates related to the G7 launch, contributing to stock volatility [3] - Early injury rates for the G7 were higher than the G6 but have since improved and remain below those of key competitors [3] Hedge Fund Interest - At the end of Q3 2025, 71 hedge fund portfolios held DexCom, an increase from 60 in the previous quarter [4]

Core Insights - DexCom, Inc. (DXCM) has not met shareholder expectations in 2025, reflecting challenges within the broader medical equipment industry [1] Company Performance - The performance of DexCom, Inc. has been underwhelming for its shareholders in the current year [1] Industry Context - The medical equipment industry as a whole is facing difficulties, which may be impacting individual companies like DexCom [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on December 29, 2025 [1] Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can submit a form or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members in the litigation [3] Group 2: Case Background - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5] - Defendants are accused of overstating the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5] - The alleged misstatements and omissions have subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4] - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [2][5] - A lead plaintiff is a representative party who directs the litigation on behalf of other class members, and a motion must be filed by December 29, 2025, to serve in this role [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that the enhancements to the G7 were overstated, and the true scope of the issues was downplayed, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4] - The public statements made by DexCom during the Class Period are alleged to have been materially false and misleading, resulting in investor damages when the truth was revealed [4]

Core Insights - DexCom, Inc. (NASDAQ:DXCM) is facing challenges due to broader weakness in the medical devices industry and increased scrutiny from the FDA and customers regarding product reliability [2] - Despite these pressures, DexCom has shown strong operational execution, with three consecutive quarters of accelerating year-over-year revenue growth and near-record new patient additions [2] - The company raised its 2025 revenue guidance, but the increase was more cautious than market expectations, leading to disappointment among investors [2] - DexCom's stock is trading near its all-time low forward earnings multiple, indicating a potential disconnect from its growth outlook [2] - Potential catalysts for DexCom include strong adoption of its newly launched 15-day sensor, expanded Medicare coverage for type-2 non-insulin patients, and clarity on the company's long-range plan [2] - The 15-day sensor is expected to contribute significantly to profitability in 2026 through margin leverage [2] Market Sentiment - Jim Cramer expressed concerns about the stock being "too rich" and highlighted the potential impact of GLP-1 medications on DexCom's market [1] - There is a belief that certain AI stocks may offer greater upside potential compared to DexCom, despite acknowledging its investment potential [2]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly rendered the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were reportedly overstated by the defendants [2] - The true scope and severity of the issues and health risks associated with the G7 devices were allegedly downplayed by the defendants [2] - The situation has subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Group 1: Bank of Nova Scotia - The Bank of Nova Scotia is considered a "very good" company by Jim Cramer, who highlighted its better-than-expected fourth-quarter results [1] - Bank of Nova Scotia shares gained 0.4% to close at $72.92 [6] Group 2: Strategy Inc - Bernstein analyst Gautam Chhugani maintained an Outperform rating for Strategy Inc but lowered the price target from $600 to $450 [2] - Strategy shares fell 0.7% to settle at $183.30 [6] Group 3: AST SpaceMobile, Inc. - Cramer described AST SpaceMobile as speculative, indicating potential for significant losses [2] - AST SpaceMobile shares rose 7.2% to settle at $84.75 [6] - The company announced the addition of two new manufacturing sites in Texas and Florida [2] Group 4: DexCom, Inc. - Cramer expressed a lack of interest in owning DexCom, despite Citigroup analyst Joanne Wuensch maintaining a Buy rating and raising the price target from $75 to $77 [3] - Dexcom shares gained 2% to close at $68.94 [6] Group 5: NRG Energy - Cramer recommended buying NRG Energy, citing its nuclear component and strong management [3] - UBS analyst William Appicelli initiated coverage on NRG Energy with a Buy rating and a price target of $211 [3] - NRG Energy shares rose 1.5% to settle at $170.64 [6] Group 6: MercadoLibre, Inc. - Cramer endorsed MercadoLibre as a buy, calling it "such a good company" [4] - BTIG analyst Marvin Fong reiterated a Buy rating on MercadoLibre with a price target of $2,750 [4] - MercadoLibre shares gained 2.5% to close at $2,019.81 [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues and health risks associated with the altered G7 devices were downplayed by the defendants [3]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - The public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [3]. - Shareholders are encouraged to register for the class action by December 26, 2025, to be eligible for potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].